764 related articles for article (PubMed ID: 26848870)
1. A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors.
Chatterjee S; Lesniak WG; Gabrielson M; Lisok A; Wharram B; Sysa-Shah P; Azad BB; Pomper MG; Nimmagadda S
Oncotarget; 2016 Mar; 7(9):10215-27. PubMed ID: 26848870
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 Detection in Tumors Using [(64)Cu]Atezolizumab with PET.
Lesniak WG; Chatterjee S; Gabrielson M; Lisok A; Wharram B; Pomper MG; Nimmagadda S
Bioconjug Chem; 2016 Sep; 27(9):2103-10. PubMed ID: 27458027
[TBL] [Abstract][Full Text] [Related]
3. Near-infrared fluorescence-labeled anti-PD-L1-mAb for tumor imaging in human colorectal cancer xenografted mice.
Zhang M; Jiang H; Zhang R; Jiang H; Xu H; Pan W; Gao X; Sun Z
J Cell Biochem; 2019 Jun; 120(6):10239-10247. PubMed ID: 30609118
[TBL] [Abstract][Full Text] [Related]
4. Radioimmunoimaging and targeting treatment in an immunocompetent murine model of triple-negative breast cancer using radiolabeled anti-programmed death-ligand 1 monoclonal antibody.
Pang X; Liu M; Wang R; Liao X; Yan P; Zhang C
J Labelled Comp Radiopharm; 2018 Sep; 61(11):826-836. PubMed ID: 29923634
[TBL] [Abstract][Full Text] [Related]
5. Peptide-Based
De Silva RA; Kumar D; Lisok A; Chatterjee S; Wharram B; Venkateswara Rao K; Mease R; Dannals RF; Pomper MG; Nimmagadda S
Mol Pharm; 2018 Sep; 15(9):3946-3952. PubMed ID: 30037229
[TBL] [Abstract][Full Text] [Related]
6. The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade.
Li HY; McSharry M; Bullock B; Nguyen TT; Kwak J; Poczobutt JM; Sippel TR; Heasley LE; Weiser-Evans MC; Clambey ET; Nemenoff RA
Cancer Immunol Res; 2017 Sep; 5(9):767-777. PubMed ID: 28819064
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 microSPECT/CT Imaging for Longitudinal Monitoring of PD-L1 Expression in Syngeneic and Humanized Mouse Models for Cancer.
Heskamp S; Wierstra PJ; Molkenboer-Kuenen JDM; Sandker GW; Thordardottir S; Cany J; Olive D; Bussink J; Boerman OC; Dolstra H; Aarntzen EHJG; Hobo WA
Cancer Immunol Res; 2019 Jan; 7(1):150-161. PubMed ID: 30459153
[TBL] [Abstract][Full Text] [Related]
8. Novel Dual-Mode NIR-II/MRI Nanoprobe Targeting PD-L1 Accurately Evaluates the Efficacy of Immunotherapy for Triple-Negative Breast Cancer.
Liu WL; Zhang YQ; Luo XJ; Zhu YY; Song L; Ming ZH; Zhang LX; Li MJ; Lv RC; Zhang GJ; Chen M
Int J Nanomedicine; 2023; 18():5141-5157. PubMed ID: 37705867
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers].
Duruisseaux M; Rouquette I; Adam J; Cortot A; Cazes A; Gibault L; Damotte D; Lantuejoul S
Ann Pathol; 2017 Feb; 37(1):61-78. PubMed ID: 28162296
[TBL] [Abstract][Full Text] [Related]
10. Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor.
Deng R; Bumbaca D; Pastuskovas CV; Boswell CA; West D; Cowan KJ; Chiu H; McBride J; Johnson C; Xin Y; Koeppen H; Leabman M; Iyer S
MAbs; 2016; 8(3):593-603. PubMed ID: 26918260
[TBL] [Abstract][Full Text] [Related]
11. Practical Immuno-PET Radiotracer Design Considerations for Human Immune Checkpoint Imaging.
Mayer AT; Natarajan A; Gordon SR; Maute RL; McCracken MN; Ring AM; Weissman IL; Gambhir SS
J Nucl Med; 2017 Apr; 58(4):538-546. PubMed ID: 27980047
[TBL] [Abstract][Full Text] [Related]
12. A fully human CXCR4 antibody demonstrates diagnostic utility and therapeutic efficacy in solid tumor xenografts.
Azad BB; Chatterjee S; Lesniak WG; Lisok A; Pullambhatla M; Bhujwalla ZM; Pomper MG; Nimmagadda S
Oncotarget; 2016 Mar; 7(11):12344-58. PubMed ID: 26848769
[TBL] [Abstract][Full Text] [Related]
13. Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers.
Broos K; Keyaerts M; Lecocq Q; Renmans D; Nguyen T; Escors D; Liston A; Raes G; Breckpot K; Devoogdt N
Oncotarget; 2017 Jun; 8(26):41932-41946. PubMed ID: 28410210
[TBL] [Abstract][Full Text] [Related]
14.
Bensch F; van der Veen EL; Lub-de Hooge MN; Jorritsma-Smit A; Boellaard R; Kok IC; Oosting SF; Schröder CP; Hiltermann TJN; van der Wekken AJ; Groen HJM; Kwee TC; Elias SG; Gietema JA; Bohorquez SS; de Crespigny A; Williams SP; Mancao C; Brouwers AH; Fine BM; de Vries EGE
Nat Med; 2018 Dec; 24(12):1852-1858. PubMed ID: 30478423
[TBL] [Abstract][Full Text] [Related]
15. Near infrared photoimmunotherapy with avelumab, an anti-programmed death-ligand 1 (PD-L1) antibody.
Nagaya T; Nakamura Y; Sato K; Harada T; Choyke PL; Hodge JW; Schlom J; Kobayashi H
Oncotarget; 2017 Jan; 8(5):8807-8817. PubMed ID: 27716622
[TBL] [Abstract][Full Text] [Related]
16. Early Phase I Study of a
Xing Y; Chand G; Liu C; Cook GJR; O'Doherty J; Zhao L; Wong NCL; Meszaros LK; Ting HH; Zhao J
J Nucl Med; 2019 Sep; 60(9):1213-1220. PubMed ID: 30796165
[TBL] [Abstract][Full Text] [Related]
17. Development of Novel ImmunoPET Tracers to Image Human PD-1 Checkpoint Expression on Tumor-Infiltrating Lymphocytes in a Humanized Mouse Model.
Natarajan A; Mayer AT; Reeves RE; Nagamine CM; Gambhir SS
Mol Imaging Biol; 2017 Dec; 19(6):903-914. PubMed ID: 28247187
[TBL] [Abstract][Full Text] [Related]
18. Non-invasive PD-L1 quantification using [
Mishra A; Gupta K; Kumar D; Lofland G; Sharma AK; Solnes LB; Rowe SP; Forde PM; Pomper MG; Gabrielson EW; Nimmagadda S
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37793856
[TBL] [Abstract][Full Text] [Related]
19. Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti-PD-L1 Antibodies.
Heskamp S; Hobo W; Molkenboer-Kuenen JD; Olive D; Oyen WJ; Dolstra H; Boerman OC
Cancer Res; 2015 Jul; 75(14):2928-36. PubMed ID: 25977331
[TBL] [Abstract][Full Text] [Related]
20. Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies.
Sui H; Ma N; Wang Y; Li H; Liu X; Su Y; Yang J
J Immunol Res; 2018; 2018():6984948. PubMed ID: 30159341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]